| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87a863132c68cf0f62015bbd5d05ab38 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2318-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2014-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94584350883ffc2adea9d87984844f1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4ca730c0714ddce8eaff712a74604db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_151fc1d014c9083bf24cb69accc00c37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcd3f97b5383ba1629d34a5533d83a15 |
| publicationDate |
2015-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2015057545-A2 |
| titleOfInvention |
Cysteine engineered fibronectin type iii domain binding molecules |
| abstract |
Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN 3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizig a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules: and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017281083-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10513686-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11781138-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7104703-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10415016-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019527540-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10329543-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11628222-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020513744-A |
| priorityDate |
2013-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |